It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The noninvasive diagnosis and monitoring of high prevalence diseases such as cardiovascular diseases, cancers and chronic respiratory diseases are currently priority objectives in the area of health. In this regard, the analysis of volatile organic compounds (VOCs) has been identified as a potential noninvasive tool for the diagnosis and surveillance of several diseases. Despite the advantages of this strategy, it is not yet a routine clinical tool. The lack of reproducible protocols for each step of the biomarker discovery phase is an obstacle of the current state. Specifically, this issue is present at the data preprocessing step. Thus, an open source workflow for preprocessing the data obtained by the analysis of exhaled breath samples using gas chromatography coupled with single quadrupole mass spectrometry (GC/MS) is presented in this paper. This workflow is based on the connection of two approaches to transform raw data into a useful matrix for statistical analysis. Moreover, this workflow includes matching compounds from breath samples with a spectral library. Three free packages (xcms, cliqueMS and eRah) written in the language R are used for this purpose. Furthermore, this paper presents a suitable protocol for exhaled breath sample collection from infants under 2 years of age for GC/MS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Murcia, Biotechnology Group, Department of Biochemistry and Molecular Biology and Immunology (B), Faculty of Chemistry, Murcia, Spain (GRID:grid.10586.3a) (ISNI:0000 0001 2287 8496); Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain (GRID:grid.452553.0)
2 University of Murcia, Biotechnology Group, Department of Biochemistry and Molecular Biology and Immunology (B), Faculty of Chemistry, Murcia, Spain (GRID:grid.10586.3a) (ISNI:0000 0001 2287 8496)
3 Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain (GRID:grid.452553.0); Arrixaca Children’s University Hospital, University of Murcia, Respiratory and Allergy Units, Murcia, Spain (GRID:grid.10586.3a) (ISNI:0000 0001 2287 8496); Health Institute Carlos III, Network of Asthma and Adverse and Allergy Reactions (ARADyAL), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)